Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

? This post by PastelDeUva discusses their experience with Minoxidil and Finasteride for hair loss treatments, which they stopped using for a year before resuming due to family's negative opinion. After restarting, they posted photos of the progression/regression of their hairline and are now planning on adding finasteride and dermarolling in order to get good results.

Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.

The conversation discusses hair loss treatments, focusing on insulin resistance, microneedling with topical melatonin, and stress reduction. Users express skepticism about the advice, preferring proven treatments like minoxidil and finasteride, while some mention alternative methods like dermal incisions and verteporfin for reducing fibrosis.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Hair loss is mainly influenced by genetics and DHT sensitivity. Treatments discussed include minoxidil, oral minoxidil, and finasteride.

The user experienced mixed results after one year on Dutasteride, with some areas of hair appearing worse and others better. They increased their Dutasteride dose to 2.5 mg daily and started using RU58841, with suggestions to add Minoxidil for improved results.

There is no permanent cure for hair loss; treatments like finasteride, minoxidil, and hair transplants require ongoing use and are not universally effective. Genetic complexity and financial incentives for ongoing treatments hinder the development of a definitive cure.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Oleic acid, microneedling, and emu oil are discussed as potential hair growth treatments, with some users expressing skepticism about their effectiveness. Minoxidil and finasteride are recommended as current reliable treatments until more proven solutions are available.

Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

Hair provides protection against head trauma, reduces skin cancer risk, helps remove heavy metals, and aids in wound healing. The conversation emphasizes the health benefits of maintaining head hair beyond cosmetic reasons.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

The user added topical minoxidil to their finasteride regimen, resulting in healthier hair and some regrowth, especially after quitting nicotine. They experienced minimal shedding and noted improvements in hairline density, finding the treatment mostly preventative.

2-deoxy-D-ribose is being explored as a hair loss treatment but is not proven effective in humans and may be costly and inconvenient. Minoxidil remains the most effective treatment.

Baldness is not an evolutionary disadvantage because it occurs after reproductive age. Treatments like Minoxidil and Finasteride are used for androgenetic alopecia but don't address the root cause.

PP405 may revive dormant hair follicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

Dutasteride may cause chronic infertility by reducing semen volume and motility, with concerns about irreversible prostate fibrosis. Users consider switching to finasteride or using treatments like minoxidil and microneedling, weighing hair preservation against fertility.

Hair follicles usually go dormant rather than die, and treatments like finasteride, minoxidil, and hormone therapy can sometimes reactivate them, though results vary. Complete regrowth is rare, especially in long-term bald areas, but some individuals see significant improvement with these treatments.

People discussed starting hair loss treatments like finasteride, dutasteride, and minoxidil due to personal experiences or comments about their hair loss. Some reported positive results, while others mentioned side effects or switching treatments.

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.